Compare · AXDX vs TXG
AXDX vs TXG
Side-by-side comparison of Accelerate Diagnostics Inc. (AXDX) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXDX and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- TXG is the larger of the two at $8.77B, about 44.5x AXDX ($197.2M).
- TXG has hit the wire 16 times in the past 4 weeks while AXDX has been quiet.
- TXG has more recent analyst coverage (25 ratings vs 1 for AXDX).
- Company
- Accelerate Diagnostics Inc.
- 10x Genomics Inc.
- Price
- $0.14+59.82%
- $66.17-1.62%
- Market cap
- $197.2M
- $8.77B
- 1M return
- -
- +13.14%
- 1Y return
- -
- +425.99%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 0
- 16
- Recent ratings
- 1
- 25
Accelerate Diagnostics Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest AXDX
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
- SEC Form 3 filed by new insider Shalhoub Paul Vincent
- Amendment: SEC Form 10-K/A filed by Accelerate Diagnostics Inc.
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)
Latest TXG
- Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
- UBS resumed coverage on 10x Genomics with a new price target
- Director Stuelpnagel John R sold $1,235,072 worth of shares (20,000 units at $61.75), decreasing direct ownership by 6% to 328,436 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by 10x Genomics Inc.
- Chief Executive Officer Saxonov Serge gifted 100 shares, decreasing direct ownership by 0.01% to 1,075,249 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- RBC Capital Mkts initiated coverage on 10x Genomics with a new price target
- Chief Executive Officer Saxonov Serge sold $667,901 worth of shares (10,486 units at $63.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 1,075,349 units (SEC Form 4)
- 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
- Chief Executive Officer Saxonov Serge sold $1,168,775 worth of shares (18,545 units at $63.02), decreasing direct ownership by 2% to 1,085,835 units (SEC Form 4) to satisfy tax liability